# Antifungal Use in Oncohematological Neutropenic Patients

> **NCT00386802** · PHASE4 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 115 (estimated)

## Conditions studied

- Invader Fungal Infection

## Interventions

- **DRUG:** Antifungal drug. VORICONAZOL. (VFEND®)

## Key facts

- **NCT ID:** NCT00386802
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-12
- **Final completion:** 2009-01
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2009-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00386802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00386802, "Antifungal Use in Oncohematological Neutropenic Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00386802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*